A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.